Fenfen and Redux - The Tentpole Story

The FDA committee meets the advisory committee meets. They vote five to three to reject Redux for approval. A few hours later, a few of the committee members go to the chair of the committee and say that they have uneasy feelings about sort of how they manage this. It's in direct conflict with a major neuroscience conference. And folks were not getting invited to speak again. So only the manufacturers showed up and the vote flips.